Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinson’s with Rob Malenka

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to basket failed.

Please try again later

Add to Wish List failed.

Please try again later

Remove from Wish List failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinson’s with Rob Malenka

Listen for free

View show details

About this listen

Matias interviews Rob Malenka.

In this episode, we discuss:

Why progress in psychiatry is slow because the brain is the most complex organ and many disorders are highly heterogeneous
The bottlenecks including weak replicability in research, academic politics, perverse incentives, and pharma’s avoidance of neuropsychiatry
How breakthroughs require early detection, rigorous science, and bridging academia with biotech through venture philanthropy
How success depends on mission-driven, ethical people who align science, capital, and patient impact.
The opportunities in neuromodulation, data-driven precision medicine, and combination therapies.

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Caitlin Ner & Nico V. Rey

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

No reviews yet